Etanercept
Brand: Enbrel®, Benepali®
NICE TA: 383
Indication: Ankylosing spondylitis (NICE TA383)
Disease category: Musculoskeletal and joint disease
Commissioning responsibility: CCG
PbR excluded: Yes
Background
Etanercept is recommended, within its marketing authorisations, as an option for treating severe active ankylosing spondylitis in adults whose disease has responded inadequately to, or who cannot tolerate, non‑steroidal anti‑inflammatory drugs.
Recommendation
LMMG recommendation: Red
Click here to find the definitions for the colour classifications
Reason for decision: Specialist medicine
Supporting documents:
Biosimilars of Etanercept (Version 1.0) (268.5 KiB)
Decisions of Lancashire local decision making groups:
| NHS Blackburn With Darwen CCG and NHS East Lancashire CCG | NHS Blackpool CCG | NHS Chorley and South Ribble CCG and NHS Greater Preston CCG | NHS Fylde and Wyre CCG | NHS Morecambe Bay CCG | NHS West Lancashire CCG |
|---|---|---|---|---|---|
Red |
Red |
Red |
Red |
Red |
Red |
